Analyst consensus rating
Spyre Therapeutics Analyst Rating: Strong Buy
Direct answer
Spyre Therapeutics's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $123.87.
Forecast evidence checked November 14, 2026.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $104.00
- Average price target
- $123.87
- High price target
- $141.00
- Low price target
- $114.00
- Low target gap
- +9.6%
- Target upside
- +19.1%
- High target gap
- +35.6%
- Target range width
- 26%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Spyre Therapeutics?
Spyre Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $123.87.
How far are Spyre Therapeutics's low and high targets from the recorded price?
The low target implies +9.6%, while the high target implies +35.6%.
How many analysts are included in Spyre Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Spyre Therapeutics's target upside or downside calculated?
The average target of $123.87 is divided by the recorded price of $104.00, then one is subtracted to produce +19.1%. This does not guarantee a future return.
When was Spyre Therapeutics's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.